Descubra el nuevo Chem-Impex: donde la innovación comienza con un vínculo.

Catalog Number:
38184
CAS Number:
103177-37-3
Pranlukast
Purity:
≥ 98 % (HPLC)
Documents
$70.91 /25 mg
Tamaño
Request Bulk Quote
Información del producto

Pranlukast is a potent leukotriene receptor antagonist that has garnered attention for its role in managing asthma and allergic rhinitis. This compound works by inhibiting the action of leukotrienes, which are inflammatory mediators that contribute to bronchoconstriction and airway inflammation. Its unique structure, featuring a chromen-8-yl moiety and a phenylbutoxy group, enhances its efficacy and selectivity, making it a valuable option for patients seeking relief from respiratory conditions.

In clinical settings, Pranlukast has been shown to improve lung function and reduce the frequency of asthma attacks, providing a significant quality of life improvement for individuals with chronic respiratory issues. Additionally, its application extends to research in inflammatory diseases, where it serves as a model compound for developing new therapies targeting similar pathways. With its favorable safety profile and effectiveness, Pranlukast stands out as a promising choice for both healthcare providers and researchers focused on respiratory health.

Número CAS
103177-37-3
Fórmula molecular
C27H23N5O4
Peso molecular
481.51
Número MDL
MFCD00864631
Punto de fusión
232 - 234 °C
Condiciones
Conservar entre 2 y 8 °C.
Información general
Número CAS
103177-37-3
Fórmula molecular
C27H23N5O4
Peso molecular
481.51
Número MDL
MFCD00864631
Punto de fusión
232 - 234 °C
Condiciones
Conservar entre 2 y 8 °C.
Propiedades
¡Pronto habrá más información sobre la propiedad!
-
Seguridad y normativas
Materiales peligrosos
-
Antibiótico
-
Regulado por la DEA
No
Advertencias
-
Aplicaciones

Pranlukast is widely utilized in research focused on

  • Asthma Management: This compound is primarily used as a leukotriene receptor antagonist, helping to reduce inflammation and bronchoconstriction in asthma patients. Its effectiveness can lead to improved breathing and reduced reliance on corticosteroids.
  • Allergy Treatment: Pranlukast is beneficial in managing allergic rhinitis by blocking the action of leukotrienes, which are involved in allergic responses. This application is particularly useful for patients seeking relief from seasonal allergies.
  • Chronic Obstructive Pulmonary Disease (COPD): The compound is being researched for its potential in alleviating symptoms of COPD, offering a new avenue for treatment in patients who experience chronic respiratory issues.
  • Combination Therapies: In clinical studies, Pranlukast is often explored in combination with other medications to enhance therapeutic outcomes for respiratory conditions, providing a synergistic effect that can improve patient care.
  • Research on Inflammatory Diseases: Beyond respiratory applications, Pranlukast is being investigated for its role in treating other inflammatory diseases, showcasing its versatility and potential in broader therapeutic contexts.

Citas